Orchestra BioMed Holdings, Inc.

Name: Orchestra BioMed Holdings, Inc. standardized financial statements, quarterly
Creator: Listed

OBIONasdaqCIK 1814114HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$88.0k, Q2 FY2026

Operating income−$22.4m, Q2 FY2026

Net income−$23.8m, Q2 FY2026

Orchestra BioMed Holdings, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	0.4	0.3	0.6	0.8	1.0	0.3	0.9	0.8	0.9	30.9	0.1	0.1
Cost of revenue	$m	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.0
Research and development	$m	8.6	8.5	9.1	11.1	11.6	11.0	13.5	13.9	14.0	16.8	15.8	16.6
Selling, general and administrative	$m	6.3	4.2	5.9	6.5	5.7	5.9	6.3	6.3	7.1	7.3	6.4	5.8
Operating income	$m	(14.5)	(12.5)	(14.4)	(16.9)	(16.3)	(16.7)	(18.9)	(19.3)	(20.3)	6.8	(22.1)	(22.4)
Interest expense	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Net income	$m	(13.3)	(12.8)	(13.5)	(16.0)	(15.4)	(16.2)	(18.8)	(19.4)	(20.8)	6.2	(20.7)	(23.8)
Diluted EPS	$ per share	(0.38)	not reported	(0.38)	(0.45)	(0.41)	not reported	(0.49)	(0.50)	(0.40)	not reported	(0.33)	(0.38)
Basic EPS	$ per share	(0.38)	not reported	(0.38)	(0.45)	(0.41)	not reported	(0.49)	(0.50)	(0.40)	not reported	(0.33)	(0.38)

Balance sheet

Cash and equivalents$20.5m, Q2 FY2026

Long-term debt$15.0m, Q1 FY2026

Shareholders' equity$19.3m, Q2 FY2026

Orchestra BioMed Holdings, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	19.1	30.6	23.3	23.7	25.6	22.3	18.3	18.7	42.0	34.7	28.4	20.5
Current assets	$m	110	89.1	76.4	66.5	68.6	69.2	51.9	35.9	97.8	108	96.2	111
Total assets	$m	116	95.2	82.6	72.4	75.3	76.2	59.1	42.8	105	115	101	116
Current liabilities	$m	21.5	11.2	10.4	14.5	16.2	16.2	15.5	17.1	20.7	16.7	13.7	13.5
Total liabilities	$m	36.7	27.2	25.4	28.3	29.1	43.2	42.2	42.5	61.1	51.5	49.7	86.3
Long-term debt	$m	10.0	not reported	not reported	not reported	not reported	15.0	15.0	15.0	15.0	15.0	15.0	not reported
Shareholders' equity	$m	79.7	68.0	57.2	44.1	46.2	33.0	16.9	0.3	43.7	53.6	41.2	19.3

Cash flow

Operating cash flow−$19.3m, Q2 FY2026

Capital expenditure$254.0k, Q2 FY2026

Orchestra BioMed Holdings, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(10.3)	(11.0)	(13.1)	(10.2)	(13.7)	(13.5)	(16.6)	(15.5)	(14.6)	(2.3)	(22.2)	(19.3)
Capital expenditure	$m	0.0	(0.0)	0.0	0.1	0.1	0.1	0.1	0.0	0.3	0.0	0.2	0.3

Diluted shares (weighted)63.81m, Q2 FY2026

Orchestra BioMed Holdings, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	20.2	27.6	34.6	35.2	35.8	35.8	37.6	38.2	38.4	52.2	62.7	63.8

Shares outstanding: 60.11m at Aug 6, 2026, from the cover of the 10-Q filed Aug 10, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. Listed shows no prices and gives no investment advice.